UroGen Pharma (URGN) announced patient-reported outcomes following treatment of patients with low-grade intermediate-risk non-muscle invasive bladder cancer, LG-IR-NMIBC, that showed ...

In a report released on April 24, Justine Telliez from Kepler Capital maintained a Hold rating on Innate Pharma SA (IPHYF – Research Report), with a price target of €3.10. The company’s ...

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME ...

Ottawa, April 25, 2025 (GLOBE NEWSWIRE) -- According to Statifacts, the global insulin delivery pens market size was exhibited at USD 26,412 million in 2024 and is projected to grow USD 58,086 ...

Pre-Open Stock Movers: Antares Pharma, Inc. (NASDAQ:ATRS) 49% HIGHER; Halozyme Therapeutics, Inc. (NASDAQ:HALO) agreed to acquire ...

BERLIN, April 25, 2025--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of ...

Drugmakers breathed a sigh of relief Wednesday after President Trump didn’t announce pharmaceutical tariffs. Plus, language in the executive order indicated medicines were exempted from the ...

Ottawa, April 25, 2025 (GLOBE NEWSWIRE) -- According to Statifacts, the global insulin delivery pens market size was exhibited at USD 26,412 million in 2024 and is projected to grow USD 58,086 million ...

PHARMA EARNINGS NOD TO TARIFFS — Major drug companies are beginning to deliver their first-quarter readouts to Wall Street analysts, revealing their expectations of how a global tariff war could ...

Regeneron has since re-filed the BCMAxCD3 drug in the U.S., and it's now awaiting a July 10 decision target date. With linvoseltamab's delayed arrival in the U.S., the multiple myeloma bispecific ...

BERLIN--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by ...

German pharmaceutical company Merck announced Monday that it has reached an agreement to acquire US-based SpringWorks Therapeutics for $3.9 billion, a move aimed at strengthening its oncology ...